Report On Honey Motivated To Malign Image Of Market Leader, Says Dabur

Ghaziabad : Dabur India Ltd. rejected the reports about the presence of cancer-causing substance in its honey and termed the claims as “motivated” and “baseless.”

A high concentration of carcinogenic material was allegedly found in the popular brand Dabur Honey, according to a Zee News report. The samples of Dabur Honey were tested at the Centre for Analysis and Learning in Livestock and Food at the National

“We stand by the purity of Dabur Honey,” Chief Executive Officer Mohit Malhotra said during a post-earnings conference call on Thursday. “Every single batch of Dabur Honey dispatched from our factories complies with all FSSAI parameters, including HMF.”

“In fact, Dabur Honey is the only leading honey brand in the country which has been granted the Agmark special certification post inspection and proper due diligence,” he said. “This certifies the purity of Dabur Honey. We are also the only Indian honey brand that is packed in (the) U.S. FDA certified facilities.”

Outside India, Dabur has a manufacturing presence in eight locations, and its products are sold in over 120 countries across the globe. “We conform with regulations of every country in the world, and there has not been any question of impurity,” Malhotra said.

Honey products contribute 6–7% to Dabur’s revenue in India and 5% to consolidated revenue, Abneesh Roy of Nuvama Wealth Management said in a note. He doesn’t expect a big impact on honey sales over the longer term, but there could be a “small” impact in the short term.

This is not the first time that Dabur’s honey has found itself embroiled in controversy for failing to pass quality tests. In 2020, the Centre for Science and Environment claimed that honey sold by 13 brands in India, including Dabur, had been found adulterated with sugar syrup.

The environment watchdog had at that time said that Dabur Honey flunked the stringent nuclear magnetic resonance test, considered the global gold standard for honey, as part of an investigation. Dabur, however, rejected the findings even then, saying that it was the only company in the country to have NMR testing equipment in its own laboratory.

The NMR tests have been made mandatory in India for honey that is meant for export as of Aug. 1, 2020.

The Food Safety and Standards Authority of India also started a pan-nation drive in 2021 to collect samples of honey and get them tested for adulteration. Queries emailed to the FSSAI remained unanswered till the time of publishing.

“There are about 65 parameters set by India’s food regulator, and Dabur complies with all of them,” Malhotra said. “So, the report is simply motivated to malign the image of the market leader.”

Malhotra highlighted that Dabur gained 500 basis points of market share since the controversy happened last time because of the CSE report, which is a “clear indication that Dabur remains a strong player”.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’